4-(2-pyrrolidin-1-ylethoxy)phenyl isothiocyanate | 50609-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2-pyrrolidin-1-ylethoxy)phenyl isothiocyanate
• 英文别名: 1-(2-(4-isothiocyanatophenoxy)ethyl)pyrrolidine；1-[2-(4-isothiocyanatophenoxy)ethyl]pyrrolidine
• CAS: 50609-00-2
• 化学式: C₁₃H₁₆N₂OS
• 分子量: 248.349
• InChiKey: WKGAFKNWVGABDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  56.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-pyrrolidin-1-ylethoxy)phenyl isothiocyanate 在 氨 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 2.33h， 生成 Flt-3 Inhibitor III
  参考文献：
  名称：

  Aromatic Interactions with Phenylalanine 691 and Cysteine 828:  A Concept for FMS-like Tyrosine Kinase-3 Inhibition. Application to the Discovery of a New Class of Potential Antileukemia Agents

  摘要：

  FLT3 kinase inhibitors are currently under investigation as a new treatment for acute myeloid leukemia. We report here a molecular concept invoking interactions between an aromatic ring and the side chains of Phe691 and Cys828, two residues of the ATP pocket, to obtain potent and specific inhibitors of this kinase. The hypothesis has been validated by the successful design of a new inhibitor prototype showing promising antiproliferative activity in cellular assays.

  DOI：

  10.1021/jm060368s
• 作为产物：
  描述：

  对氨基苯酚 在 sodium hydroxide 、 碳酸氢钠 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-(2-pyrrolidin-1-ylethoxy)phenyl isothiocyanate
  参考文献：
  名称：

  Aromatic Interactions with Phenylalanine 691 and Cysteine 828:  A Concept for FMS-like Tyrosine Kinase-3 Inhibition. Application to the Discovery of a New Class of Potential Antileukemia Agents

  摘要：

  FLT3 kinase inhibitors are currently under investigation as a new treatment for acute myeloid leukemia. We report here a molecular concept invoking interactions between an aromatic ring and the side chains of Phe691 and Cys828, two residues of the ATP pocket, to obtain potent and specific inhibitors of this kinase. The hypothesis has been validated by the successful design of a new inhibitor prototype showing promising antiproliferative activity in cellular assays.

  DOI：

  10.1021/jm060368s

文献信息

• DIAMINOTHIAZOLES
  申请人：——

  公开号：US20040006058A1

  公开（公告）日：2004-01-08

  The present invention is directed to novel diaminothiazoles of formula 1 These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型的formula1的二氨基噻唑化合物。这些化合物抑制细胞周期依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面具有用途。本发明还涉及含有这些化合物的药物组合物，以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤的方法。
• Anilinobenzothiazoles as antidepressants
  申请人：The Boots Company

  公开号：US03957999A1

  公开（公告）日：1976-05-18

  New anilinobenzothiazoles are used for treating depression.

  新的苯并噻唑胺类化合物被用于治疗抑郁症。
• [EN] THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS<br/>[FR] DERIVES DE THIAZOLE ET DE PYRAZOLE EN TANT QU'INHIBITEURS DE LA KINASE FLT-3
  申请人：NOVARTIS AG

  公开号：WO2005047273A1

  公开（公告）日：2005-05-26

  The invention relates to thiazole and pyrazole derivatives of formula (I) wherein Q is S and X is C, or Q is CH and X is N; R1 is unsubtituted or substituted phenyl; and R2 is unsubstituted or substituted aryl or heteroaryl; oa a salt of the said compounds, and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour disease, in particular such diseases which respond to an inhibition of the FIt-3 kinase.

  该发明涉及公式(I)的噻唑和吡唑衍生物，其中Q为S且X为C，或者Q为CH且X为N；R1为未取代或取代的苯基；R2为未取代或取代的芳基或杂环芳基；或者该化合物的盐；以及其制备方法，包括含有这种衍生物的药物组合物，以及利用这种衍生物制备用于治疗增殖性疾病，如肿瘤疾病，特别是对FIt-3激酶抑制有响应的疾病的药物组合物。
• Diaminothiazoles
  申请人：Hoffmann-La Roches

  公开号：US06818663B2

  公开（公告）日：2004-11-16

  The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型二氨基噻唑的公式，这些化合物抑制细胞周期蛋白依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是实体肿瘤方面非常有用。本发明还涉及含有这些化合物的制药组合物以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺、结肠和前列腺肿瘤的方法。
• DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS
  申请人：Goff Dane

  公开号：US20080227789A1

  公开（公告）日：2008-09-18

  Diaminothiazoles and pharmaceutical compositions containing them are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the diaminothiazoles in treating diseases or conditions associated with Axl activity are also disclosed.

  本发明揭示了二氨基噻唑类化合物和含有它们的药物组合物，作为抑制受体蛋白酪氨酸激酶Axl活性的有用药物。还揭示了使用二氨基噻唑类化合物治疗与Axl活性相关的疾病或病症的方法。